Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-10-30
2010-10-05
Schnizer, Richard (Department: 1635)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093600, C424S093100, C435S456000
Reexamination Certificate
active
07807147
ABSTRACT:
The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to tumors and have the ability to cause tumor necrosis.
REFERENCES:
patent: 5091309 (1992-02-01), Schlesinger et al.
patent: 5217879 (1993-06-01), Huang et al.
patent: 5631236 (1997-05-01), Woo et al.
patent: 5739026 (1998-04-01), Garoff
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5814482 (1998-09-01), Dubensky et al.
patent: 5843723 (1998-12-01), Dubensky, Jr. et al.
patent: 6015686 (2000-01-01), Dubensky, Jr. et al.
patent: 6015694 (2000-01-01), Dubensky, Jr. et al.
patent: 6190666 (2001-02-01), Garoff et al.
patent: 6224879 (2001-05-01), Sjoberg et al.
patent: 6242259 (2001-06-01), Polo et al.
patent: 6329201 (2001-12-01), Polo et al.
patent: 6342372 (2002-01-01), Dubensky, Jr. et al.
patent: 6376236 (2002-04-01), Dubensky, Jr. et al.
patent: 6391632 (2002-05-01), Dubensky, Jr. et al.
patent: 6426196 (2002-07-01), Dubensky, Jr. et al.
patent: 6451592 (2002-09-01), Dubensky, Jr. et al.
patent: 6458560 (2002-10-01), Dubensky, Jr. et al.
patent: 6465634 (2002-10-01), Dubensky, Jr. et al.
patent: 6566093 (2003-05-01), Liljestrom et al.
patent: 6592874 (2003-07-01), Schlesinger et al.
patent: 6692750 (2004-02-01), Sjoberg et al.
patent: 6730297 (2004-05-01), Davidson et al.
patent: 6770283 (2004-08-01), Garoff et al.
patent: WO-99/18226 (1999-04-01), None
patent: WO 99/18799 (1999-04-01), None
patent: WO 99/44423 (1999-09-01), None
patent: WO 99/44423 (1999-09-01), None
patent: WO-00/62735 (2000-10-01), None
patent: 02/074920 (2002-09-01), None
Lundstrom (Gene Therapy 12: S92-S97, 2005).
Tseng et al (Nature Biotechnology 22(1): 70-78, 2004).
Karpf et al (Virology 240: 193-201, 1998).
Tseng et al (Nature Biotechnology 22(1): 70-77, 2004).
Frolov (J. Virol. 68(3): 1721-1727, 1994).
Perri et al (J. Virol. 74(20):9802-9807, 2000).
Miller et al. (FASEB J. 9: 190-199, 1995).
Deonarain (Exp. Opin. Ther. Patents 8(1):53-69, 1998).
Verma et al (Nature 389: 239-242, 1997).
Crystal (Science 270: 404-410, 1995).
Pouton et al (Adv. Drug Del. Rev. 46: 187-203, 2001).
Read et al (Adv. Gen. 53:19-46, 2005).
Higashikawa et al (Virology 280: 124-131, 2001).
De Polo et al, J. Virol. 73 :6708-6714, 1999).
Alemany et al (J. Gen. Virol 81: 2605-2609, 2000).
Sung et al Mol. Ther. 3: 757-767, 2001).
Unno et al (Clin. Cancer Res. 11(12): 4553-4560, 2005).
Smerdou et al (J. Virol. 73: 1092-1098, 1999).
Asselin-Paturel et al (Gene Therapy 5: 606-615, 1998).
Zhang et al (Gene Therapy 4: 367-374, 1997).
Leitner et al (Cancer Research 60: 51-55, 2000).
Murphy et al (Gene Therapy 7: 1477-1482, 2000).
Wang, et al. “High-Affinity Laminin Receptor Is a Receptor for Sindbis Virus in Mammalian Cells.” Journal of Virology, vol. 66, No. 8, Aug. 1992, pp. 4992-5001.
Jan, et al. “Induction of Apoptosis by Sindbis Virus Occurs at Cell Entry and Does Not Require Virus Replication.” Journal of Virology, vol. 73, No. 12, Dec. 1999, pp. 10296-10302.
Campo, et al. “Detection of Laminin Receptor mRNA in Human Cancer Cell Lines and Colorectal Tissues by In Situ Hybridization.” American Journal of Pathology, vol. 141, No. 5, Nov. 1992, pp. 1073-1083.
Perri, Sylvia et al. “Replicon Vectors Derived from Sindbis Virus and Semliki Forest Virus That Establish Persistent Replication in Host Cells.” Journal of Virology, Oct. 2000, pp. 9802-9807, vol. 74, No. 20.
Leitner, Wolfgang W. et al. “Enhancement of Tumor-specific Immune Response With Plasmid DNA Replicon Vectors.” Cancer Research, Jan. 1, 2000, pp. 51-55.
Hariharan, Mangala J. et al. “DNA Immunization Against Herpes Simplex Virus: Enhanced Efficacy Using a Sindbis Virus-Based Vector.” Journal of Virology, Feb. 1998, pp. 950-958, vol. 72, No. 2.
Gardner, Jason P. et al. “Infection of Human Dendritic Cells by a Sindbis Virus Replicon Vector Is Determined by a Single Amino Acid Substitution in the E2 Glycoprotein.” Journal of Virology, Dec. 2000, pp. 11849-11857, vol. 74, No. 24.
Polo, John M. et al. “Stable Alphavirus Packaging Cell Lines for Sindbis Virus- and Semliki Forest Virus-Derived Vectors.” Proc. Natl. Acad. Sci. USA, Apr. 1999, pp. 4598-4603, vol. 96.
Schlesigner, Sondra et al. “Alphavirus Vectors for Gene Expression and Vaccines.” Current Opinion in Biotechnology, 1999, pp. 434-439.
Dubensky, Thomas W., Jr. et al. “Sindbis Virus DNA-Based Expression Vectors: Utility for In Vitro and In Vivo Gene Transfer.” Journal of Virology, Jan. 1996, pp. 508-519, vol. 70, No. 1.
Xiong, Cheng et al. “Sindbis Virus: An Efficient, Broad Host Range Vector for Gene Expression in Animal Cells.” Science, Mar. 3, 1989, pp. 1188-1191, vol. 243.
Levis, Robin et al. “Engineered Defective Interfering RNAs of Sindbis Virus Express Bacterial Chloramphenicol Acetyltransferase in Avian Cells.” Proc. Natl. Acad. Sci. USA, Jul. 1987, pp. 4811-4815, vol. 84.
Ying H. et al., “Cancer Therapy Using a Self-Replicating RNA Vaccine”, Nature Medicine, Jul. 1999, pp. 823-827, vol. 5, No. 7, Nature Publishing Group, New York, USA.
Schlesinger S. et al., “Alphavirus Vectors for Gene Expression and Vaccines”, Current Opinion in Biotechnology, Oct. 1999, pp. 434-439, vol. 10, No. 5, London, GB.
Klimp et al, “Activation of Peritoneal Cells Upon in Vivo Transfection with a Recombinant Alphavirus Expressing GM-CSF,”Gene Therapy, Feb. 2000, vol. 8, No. 4, pp. 300-307.
Leitner et al, “Enhancement of Tumor-specific Immune Response with Plasmid DNA Replicon Vectors,”Cancer Research, Jan. 1, 2000, vol. 60, No. 1, pp. 51-55.
Li et al, “Rescue of Sindbis Virus-Specific RNA Replication and Transcription by Using a Vaccinia Virus Recombinant,”Journal of Virology, Dec. 1991, vol. 65, No. 12, pp. 6714-6723.
Cherig et al, “Cancer Immunotherapy Using Sindbis Virus Replicon Particles Encoding a VP22-Antigen Fusion,”Human Gene Therapy, Mar. 1, 2002, vol. 13, No. 4, pp. 553-568.
Velders et al., “Eradication of Established Tumors by Vaccination with Venezuelan Equine Encephalitis Virus Replicon Particles Delivering Human Papillomavirus 16 E7 RNA,”Cancer Research, Nov. 1, 2001, vol. 61, No. 21, pp. 7861-7867.
Wickham, Tom, 1997. “Short-order Sindbis vector targeting”. Nature Biotechnology 15: 717.
Korokhov, et al., 2003. “Targeting of Adenovirus via Genetic Modification of the Viral Capsid Combined with a Protein Bridge”. Journal of Virology 77(24): 12937-12940.
Henning, et al., 2002. “Genetic Modification of Adenovirus 5 Tropism by a Novel Class of Ligands Based on a Three-Helix Bundle Scaffold Derived from Staphylococcal Protein A”. Human Gene Therapy 13: 1427-1439.
K. Imahori and T. Yamakawa, Editors, Dictionary of Biochemistry, 3rd edition, Tokyo Kagaku Doujin, p. 689.
Lin, et al, 1999. “Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.” Cancer Research 56(1). Biosis abstract No. PREV199698682591.
Iijima, et al, 1999. “Cell-Specific Targeting of a Thymidine Kinase/Ganciclovir Gene Therapy System Using a Recombinant Sindbis Virus Vector.” Int. J. Cancer 80: 110-118.
Fish & Richardson P.C.
New York University
Schnizer Richard
LandOfFree
Tumor therapy with high affinity laminin receptor-targeted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor therapy with high affinity laminin receptor-targeted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor therapy with high affinity laminin receptor-targeted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4195536